Brexpiprazole as a New Serotonin –Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels
by Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital in Hiroshima, Japan. Dr. Nagamine is with the Department of Psychiatric Internal Medicine, Sunlight Brain Research Center in Yamaguchi, Japan. Funding: No funding was provided for this study. Disclosures: The authors have no […]
The post Brexpiprazole as a New Serotonin–Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels appeared first on Innovations in Clinical Neuroscience.
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Drug Development Original Research Schizophrenia antipsychotics aripiprazole brexpiprazole metabolism olanzapine paliperidone Prolactin Source Type: research
More News: Abilify | Brain | Funding | Hospitals | Internal Medicine | Invega | Japan Health | Neurology | Neuroscience | Psychiatry | Schizophrenia | Study | Zyprexa